Presentation is loading. Please wait.

Presentation is loading. Please wait.

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

Similar presentations


Presentation on theme: "What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy."— Presentation transcript:

1 What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy

2

3 Treatment Options for AML Patients Ineligible for Intensive CT

4 NCCN Clinical Practice Guidelines: AML

5 AML Patients Ineligible for Intensive CT: Challenges of Traditional Therapy

6 Venetoclax Mechanism of Action

7 Availability of Venetoclax

8 Venetoclax + HMAs in Elderly Patients With Untreated AML: Study Design

9 Venetoclax + HMAs in Elderly Patients With Untreated AML: Responses

10 Venetoclax + HMAs in Elderly Patients With Untreated AML: Serious AEs

11 Assessing Fitness and Making Treatment Decisions

12 Phase 1/2 Study of Venetoclax with LDAC in Treatment-Naive, Elderly Patients with AML Unfit for Intensive CT: 1-Year Outcomes

13 Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with AML Unfit for Intensive CT: 1-Year Outcomes (cont)

14 Glasdegib + LDAC vs AZA or DEC Among AML Patients Ineligible to Receive Intensive CT

15 Glasdegib Mechanism of Action

16 Glasdegib + LDAC vs AZA or DEC Among AML Patients Ineligible to Receive Intensive CT: CR Results

17 Glasdegib: Potential Role in AML Treatment

18 Resurgence of Nontargeted Therapy for AML Treatment

19 Gemtuzumab Ozogamicin vs BSC In Older Patients With AML Unsuitable for Intensive CT: EORTC-GIMEMA AML-19 Trial

20 Gemtuzumab Ozogamicin vs BSC In Older Patients With AML Unsuitable for Intensive CT: EORTC-GIMEMA AML-19 Trial

21 Gemtuzumab Ozogamicin: Potential Role in AML Treatment

22 IDH Inhibitors In AML

23 Availability of IDH Inhibitors

24 Ivosidenib In Patients with IDH1-Mutant Untreated AML: Results From a Phase 1 Dose Escalation and Expansion Study

25 Unanswered Questions for Treating AML Patients Ineligible for Intensive CT

26 Venetoclax + HMAs in Elderly Patients With Untreated AML: Responses

27 FLT3 Inhibitors In AML

28 Phase 3 Study of Quizartinib vs SOC in FLT3-ITD R-R AML: QUANTUM-R

29 Gilteritinib In Newly Diagnosed FLT3 Mutated AML Patients Ineligible for Intensive Induction CT: Data From Safety Cohort

30 Mutational Co-Occurrence in AML

31 FLT3 Inhibitors: Potential Role in AML Treatment

32 Fit vs Unfit: How Do You Decide?

33 Need For Assessments of Fitness In the Future?

34 Evaluating MRD In AML

35 High MRD-Negative Rates Seen with Venetoclax in Patients With AML

36 Conclusions

37 Abbreviations

38 Abbreviations (cont)

39 Abbreviations (cont)


Download ppt "What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy."

Similar presentations


Ads by Google